The Lynx Group
Cholangiocarcinoma News

Does Adjuvant Chemoradiation Benefit Patients with Lymph Node–Positive Biliary Tract Cancer? A Secondary Analysis of SWOG S0809

2021 Year in Review: Cholangiocarcinoma — December 17, 2021

Results of the secondary analysis of the SWOG S0809 trial indicate that nodal status did not impact survival outcomes achieved with adjuvant chemoradiation postresection in patients with extrahepatic CCA or gallbladder cancer.

The phase 2 SWOG S0809 Intergroup Trial had previously demonstrated improved overall survival (OS) with adjuvant treatment with capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in patients with extrahepatic cholangiocarcinoma (CCA) or gallbladder cancer (GBC) compared with historical controls. Secondary analysis of SWOG S0809 ( Identifier: NCT00789958) evaluated the effect of adjuvant chemoradiation on node-positive patients. Results of the analysis were presented at the 2021 American Society of Clinical Oncology Annual Meeting.

In this analysis, patients with stage pT2-4, N+, or positive-margin resected extrahepatic CCA or GBC were included. Adjuvant chemotherapy comprised 4 cycles of gemcitabine (1000 mg/m2 on day 1 and day 8) and capecitabine (1500 mg/m2/day on days 1-14) every 21 days, followed by concurrent capecitabine (1330 mg/m2/day) and radiotherapy (45 Gy to regional lymphatics; 52.5-59.4 Gy to tumor bed). Correlations among nodal status, resection margin, and other clinicopathologic factors; patterns of recurrence; and survival were analyzed. Cox regression models were used to estimate the prognostic significance of nodal status.

A total of 69 patients were included in the analysis—66.7% (46 of 69) of the patients with extrahepatic CCA and 33.3% (23 of 69) of the participants with GBC. Overall, 24 patients had N0 disease and 45 had N1 disease. The patient characteristics of the N0 and N1 cohorts were largely comparable. Those in the N0 cohort were predominantly female (70.8%), whereas those in the N1 cohort were mostly male (55.6%; P = .04). The N1 cohort mainly had extrahepatic CCA (73.9%), and 50% of the N0 cohort had GBC.

Nodal status did not significantly impact OS or disease-free survival (DFS). The 2-year OS was similar between the N0 and N1 tumor cohorts (70.6% vs 60.9%, respectively; P = .11), as was 2-year DFS (62.5% vs 49.8%, respectively; P = .20). The 2-year DFS in patients in the N1 tumor cohort, however, was significantly prolonged compared with the historical rate (49.8% vs 29.7%, respectively; P = .004). N1 tumors compared with N0 tumors showed similar 2-year local recurrence rates (11.1% vs 8.3%, respectively; P = .88) but higher 2-year distant recurrence rates (42.2% vs 25.0%, respectively; P = .04).

Based on these results, the investigators concluded that adjuvant chemoradiation postresection provides favorable outcomes in patients with extrahepatic CCA and GBC, regardless of nodal status, with a positive impact on local control in patients with N1 tumors.

Source: Gholami S, Duon MT, Horowitz DP, et al. Does adjuvant chemoradiation benefit patients with lymph node-positive biliary tract cancer? A secondary analysis of SWOG S0809. J Clin Oncol. 2021;39(suppl_15):4104-4104.

Related Items

A Phase 1/2 Study of the Safety and Efficacy of the Arginase Inhibitor INCB001158 plus Chemotherapy in Patients with Advanced Biliary Tract Cancer
2021 Year in Review: Cholangiocarcinoma
Results of an open-label, phase 1/2 study indicate that addition of INCB001158 to the standard gemcitabine/cisplatin backbone was tolerable, did not result in significant additional toxicity, and showed modest clinical activity in the biliary tract cancers cohort.
Lenvatinib plus Pembrolizumab for Patients with Previously Treated Biliary Tract Cancers in the Multicohort Phase 2 LEAP-005 Study
2021 Year in Review: Cholangiocarcinoma
Results of the phase 2 LEAP-005 study suggest that lenvatinib plus pembrolizumab shows promising antitumor activity and manageable toxicity in previously treated patients with advanced biliary tract cancers.
Zanidatamab (ZW25) in HER2-Positive Biliary Tract Cancers: Results from a Phase 1 Study
2021 Year in Review: Cholangiocarcinoma
Results from a first-in-human, phase 1 study have shown that the bispecific HER2-targeted antibody zanidatamab is well-tolerated and has antitumor activity in patients with HER2-overexpressing biliary tract cancers.
Phase 2a MyPathway Results of Pertuzumab plus Trastuzumab for the Treatment of HER2-Positive Metastatic Biliary Tract Cancer
2021 Year in Review: Cholangiocarcinoma
Results of an ongoing, phase 2a, multiple-basket study (MyPathway) showed that dual HER2-targeted therapy with pertuzumab plus trastuzumab was well-tolerated in patients with previously treated HER2-positive metastatic biliary tract cancer.
Liposomal Irinotecan in Combination with 5-Fluorouracil and Leucovorin for Patients with Metastatic Biliary Tract Cancer After Progression on Gemcitabine plus Cisplatin: A Multicenter, Comparative, Randomized, Phase 2b Study (NIFTY)
2021 Year in Review: Cholangiocarcinoma
Results of the NIFTY trial demonstrated that liposomal irinotecan plus 5-fluorouracil and leucovorin significantly improved efficacy outcomes compared with 5-fluorouracil plus leucovorin alone in patients with biliary tract cancer who progressed on prior gemcitabine/cisplatin, with a manageable adverse event profile.
Liposomal Irinotecan plus 5-Fluorouracil/Leucovorin or Gemcitabine/Cisplatin in Patients with Advanced Biliary Tract Cancer (NIFE Trial)
2021 Year in Review: Cholangiocarcinoma
The phase 2 NIFE study compared a liposomal irinotecan plus fluorouracil and leucovorin regimen with standard-of-care gemcitabine/cisplatin in patients with advanced biliary tract cancer.
Role of ctDNA to Predict Risk for Recurrence Following Potentially Curative Resection of Biliary Tract and Pancreatic Malignancies
2021 Year in Review: Cholangiocarcinoma
Results of a pilot study demonstrate the feasibility of ctDNA testing and the prognostic value of ctDNA following potentially curative resection in patients with pancreatic/biliary tract malignancies.
Efficacy and Safety of Nab-Paclitaxel plus Gemcitabine/Cisplatin in Korean Patients with Advanced Biliary Tract Cancers
2021 Year in Review: Cholangiocarcinoma
Real-world retrospective evidence from Korean patients with advanced biliary tract cancer indicates that efficacy and safety with nab-paclitaxel plus gemcitabine/cisplatin combination were consistent with those previously reported in clinical trials.
First-Line Immunotherapy plus Chemotherapy Significantly Improves Survival in Advanced Biliary Tract Cancer
Web Exclusives
On October 25, 2021, AstraZeneca announced high-level positive results from the phase 3 clinical trial TOPAZ-1, demonstrating that adding the immunotherapy durvalumab (Imfinzi) to first-line standard-of-care chemotherapy leads to a statistically significant and clinically meaningful overall survival (OS) benefit versus chemotherapy alone in patients with advanced biliary tract cancer.
Hot Topics in Cholangiocarcinoma and Biliary Tract Cancers: ASCO Highlights
September/October 2021, Vol 2, No 3
At the CCA Summit during the 2021 Annual Meeting of the American Society of Clinical Oncology (ASCO), Mitesh J. Borad, MD, Associate Professor of Medicine, Mayo Clinic, Phoenix, AZ, reviewed some of the key topics presented at ASCO 2021 related to cholangiocarcinoma (CCA) and other biliary tract cancers. Before turning to the specific presentations, Dr Borad welcomed the May 28, 2021, FDA approval of infigratinib (Truseltiq) for patients with advanced or metastatic CCA and FGFR2 fusions or rearrangements. Infigratinib follows pemigatinib (Pemazyre) as the second targeted therapy now available for this patient population.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: